Company Overview

**Industry Sector:** Oncology Companion Diagnostic/Therapeutic

**Company Overview:** Eutropics Pharmaceuticals, Inc. is an early stage biopharmaceutical company that is developing drugs for the treatment of cancer and a companion diagnostic assay licensed from the Dana Farber Cancer Institute (DFCI). Eutropics’ first in class compounds selectively trigger apoptosis in cancer cells while our proprietary diagnostic assay, BH3 identifies cancer patients who are most likely to respond to this new class of compounds as well as other experimental and standard of care treatments.

**Target Market(s):** Partnering pharmaceutical and diagnostics companies as well as oncology physicians, patients and payers

Key Value Drivers

**Technology:** Eutropics is using high resolution biochemical assays and computational models as well as the insights from the BH3 profiling technology to guide the SAR of our lead compound series. Our approach enables identification of highly targeted compounds that surpass those from competing programs.

**Competitive Advantage:** Eutropics has discovered a compound that is highly active against myeloid cell factor 1 (Mcl-1) recognized as a key factor in causing blood and other cancers. In parallel we have developed proprietary assays to determine if a cancer cell is in fact dependent on this protein for survival, or whether the cancer cell is dependent on other proteins. These assays both enable the development of the drugs that accurately target these proteins to trigger tumor cell death and predict when they will work. Thus, these assays are translational tools from the bench to the clinic that allow the identification of patients whose tumors are most likely to respond to a given therapeutic, thereby accelerating clinical progress and leading to more specific and effective drugs.

**Plan & Strategy:** Eutropics is in discussion with potential pharma partners who will support the clinical development of lead compound and of our diagnostic test.

Management

**Leadership:**
Michael Cardone, PhD, President and CEO
David Richard, PhD, Director of Drug Development
Tom Atwood, MBA, Chief Financial Officer
Bill Pierceall, PhD, Director of Oncology

**Business Advisory Board**
Maggie LeFlore, PhD Partner MedImmune Ventures
Phyllis Whiteley, PhD Executive in Residence Mohr Davidow
Robert Curtis, PharmD, Former CEO HistoRx
Giulio Draetta, MD, PhD  Director of Applied Cancer Research MD Anderson

**Scientific Advisory Board:**
Anthony Letai, MD, Ph.D. (Co-founder) Professor of Medicine at DFCI
Ken Anderson, MD, Professor of Medicine at DFCI
Alan D’Andrea: Professor of Medicine at DFCI
Gerhard Wagner, PhD. Professor of Biophysics and Pharmacology at Harvard
Michael Andreeff, MD, PhD, Professor of Medicine at MD Anderson
Lames Bradner, MD, PhD, Professor of Medicine at DFCI

Eutropics Product Pipeline